Oncology Videos

Videos

Videos

IDO1 Inhibition Combined With Radiotherapy and Nivolumab Demonstrates Safety in Newly Diagnosed Glioblastoma

07/15/2026

Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...

Rimas Lukas, MD, discusses...

07/15/2026

Oncology

Videos

Intratumoral Phosphorus-32 Enhances FOLFIRINOX in Locally Advanced Pancreatic Cancer

07/15/2026

Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...

Michele Milella, MD, discusses...

07/15/2026

Oncology

Videos

MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma

07/15/2026

Peter Voorhees, MD

Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...

Peter Voorhees, MD, discusses...

07/15/2026

Oncology

Videos

Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer

07/14/2026

Annalice Gandini

Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...

Annalice Gandini, IRCCS,...

07/14/2026

Oncology

Videos

ctDNA MRD Testing in Lymphoma: Clinical Utility and Applications

07/06/2026

David Russler-Germain, MD, PhD

Dr David Russler-Germain explains how ctDNA–based minimal residual disease testing is helping refine post-treatment risk stratification, detect relapse earlier, and guide more personalized treatment decisions in diffuse large B-cell lymphoma,...

Dr David Russler-Germain...

07/06/2026

Oncology

Videos

ctDNA MRD Testing in Lymphoma: What It Is and How It Works

07/06/2026

David Russler-Germain, MD, PhD

Dr David Russler-Germain explains how ctDNA–based MRD testing enables highly sensitive, personalized detection of residual disease and is emerging as a valuable tool for assessing treatment response, predicting relapse risk, and guiding...

Dr David Russler-Germain...

07/06/2026

Oncology

Videos

Detecting Residual Disease in Lymphoma: Current and Emerging Tools

07/06/2026

David Russler-Germain, MD, PhD

Dr David Russler-Germain explains how ctDNA–based MRD testing is emerging as a more sensitive and accurate tool than PET/CT imaging for predicting relapse risk and assessing remission in DLBCL.

Dr David Russler-Germain...

07/06/2026

Oncology

Videos

Clinical Utility of ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer

07/01/2026

Gunnar Folprecht, MD, PhD

Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...

Gunnar Folprecht, MD, PhD,...

07/01/2026

Oncology

Videos

Ten-Year Outcomes With Tisagenlecleucel Demonstrate Durable Remissions in B-Cell Lymphoma

07/01/2026

Marco Ruella, MD

Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...

Marco Ruella, MD, discusses...

07/01/2026

Oncology

Videos

When Standard Therapy Is Not Feasible in Stage III Non–Small Cell Lung Cancer

06/30/2026

Edgardo Santos, MD

Edgardo Santos, MD, reviews the clinical decision-making behind the management of a patient with unresectable stage III KRAS G12C–mutated, PD-L1–high non–small cell lung cancer, highlighting the roles of molecular profiling, radiation...

Edgardo Santos, MD, reviews the...

06/30/2026

Oncology

Recent News

FDA Approval

FDA Approves Gedatolisib-Based Regimens for PIK3CA Wild-Type HR-Positive, HER2-Negative Advanced Breast Cancer

07/14/2026

Stephanie Holland

The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...

The FDA approved gedatolisib in...

07/14/2026

Oncology

FDA Approval

FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors

07/14/2026

Stephanie Holland

The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...

The FDA granted traditional...

07/14/2026

Oncology

News

De-escalated Paclitaxel, Trastuzumab, and Pertuzumab Yield Excellent Long-Term Outcomes in HER2-Positive Breast Cancer

07/14/2026

Stephanie Holland

A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...

A prespecified analysis of the...

07/14/2026

Oncology

FDA Approval

FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome

07/13/2026

Stephanie Holland

The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...

The FDA approved ENNUMO, a...

07/13/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma

07/13/2026

Stephanie Holland

The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...

The FDA accepted the new drug...

07/13/2026

Oncology

News

Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer

07/10/2026

Stephanie Holland

Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...

Interim results from the phase...

07/10/2026

Oncology

FDA Approval

FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma

07/10/2026

Emily Estrada

The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

The FDA has approved...

07/10/2026

Oncology

News

Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...

A multicenter real-world study...

07/09/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology